XTL Biopharmaceuticals Ltd. (XTLB)

NASDAQ: XTLB · IEX Real-Time Price · USD
0.00 (0.00%)
At close: Dec 6, 2022 12:00 AM
+0.03 (2.46%)
After-hours: Dec 7, 2022 4:00 PM EST
Market Cap 7.03M
Revenue (ttm) n/a
Net Income (ttm) 435,000
Shares Out 5.45M
EPS (ttm) 0.29
PE Ratio 4.21
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2
Open 1.24
Previous Close 1.22
Day's Range 1.12 - 1.24
52-Week Range 0.85 - 3.2
Beta 0.96
Analysts n/a
Price Target n/a
Earnings Date Dec 7, 2022

About XTLB

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and change... [Read more]

Industry Biotechnology
IPO Date Sep 1, 2005
CEO Joshua Levine
Country Israel
Stock Exchange NASDAQ
Ticker Symbol XTLB
Full Company Profile

Financial Performance

Financial Statements


Dr. Morris C. Laster Files Preliminary Proxy Statement Nominating Two Highly-Qualified Individuals For Election To Bo...

JERUSALEM, Sept. 20, 2021 /PRNewswire/ -- Dr. Morris C.

Other symbols: SCPS
1 year ago - PRNewsWire